543 related articles for article (PubMed ID: 30357752)
1. BCL3 Expression Is a Potential Prognostic and Predictive Biomarker in Acute Myeloid Leukemia of FAB Subtype M2.
Niu Y; Yang X; Chen Y; Zhang L; Jin X; Tang Y; Li L; Yu L; Guo Y; Wang H
Pathol Oncol Res; 2019 Apr; 25(2):541-548. PubMed ID: 30357752
[TBL] [Abstract][Full Text] [Related]
2. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
3. Serum MicroRNA-370 as a potential diagnostic and prognostic biomarker for pediatric acute myeloid leukemia.
Lin X; Wang Z; Wang Y; Feng W
Int J Clin Exp Pathol; 2015; 8(11):14658-66. PubMed ID: 26823789
[TBL] [Abstract][Full Text] [Related]
4. High expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) is associated with poor prognosis in acute myeloid leukemia.
Zhou LY; Yin JY; Tang Q; Zhai LL; Zhang TJ; Wang YX; Yang DQ; Qian J; Lin J; Deng ZQ
Int J Clin Exp Pathol; 2015; 8(12):16073-80. PubMed ID: 26884884
[TBL] [Abstract][Full Text] [Related]
5. Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia.
Zhou JD; Yao DM; Han L; Xiao GF; Guo H; Zhang TJ; Li XX; Yuan Q; Yang L; Lin J; Qian J
Tumour Biol; 2017 Apr; 39(4):1010428317699123. PubMed ID: 28443469
[TBL] [Abstract][Full Text] [Related]
6. Distinct prognostic values of Annexin family members expression in acute myeloid leukemia.
Niu Y; Yang X; Chen Y; Jin X; Xie Y; Tang Y; Li L; Liu S; Guo Y; Li X; Duan L; Wang H
Clin Transl Oncol; 2019 Sep; 21(9):1186-1196. PubMed ID: 30694461
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia.
Wang Z; Hong Z; Gao F; Feng W
Mol Cell Biochem; 2013 Nov; 383(1-2):59-65. PubMed ID: 23864342
[TBL] [Abstract][Full Text] [Related]
8. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
9. PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia.
Cheng H; Huang C; Xu X; Hu X; Gong S; Tang G; Song X; Zhang W; Wang J; Chen L; Yang J
J Transl Med; 2017 Aug; 15(1):179. PubMed ID: 28851457
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category.
Ghannadan M; Wimazal F; Simonitsch I; Sperr WR; Mayerhofer M; Sillaber C; Hauswirth AW; Gadner H; Chott A; Horny HP; Lechner K; Valent P
Am J Clin Pathol; 2003 May; 119(5):663-71. PubMed ID: 12760284
[TBL] [Abstract][Full Text] [Related]
11. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
12. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
13. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
14. High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk.
Xu N; Chen WM; Li LD; Long LY; Wang X; Jiang Q; Jiang H; Huang XJ; Qin YZ
Clin Exp Med; 2023 Oct; 23(6):2629-2638. PubMed ID: 36637581
[TBL] [Abstract][Full Text] [Related]
15. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
[TBL] [Abstract][Full Text] [Related]
16. De Novo Acute Myeloid Leukemia in Adults: Suppression of MicroRNA-223 is Independent of LMO2 Protein Expression BUT Associate With Adverse Cytogenetic Profile and Undifferentiated Blast Morphology.
Akhter A; Patel JL; Farooq F; Qureshi A; Taher-Rad MS; Elyamany G; Al-Zahrani AM; Rashid-Kolvear F; Mansoor A
Appl Immunohistochem Mol Morphol; 2015; 23(10):733-9. PubMed ID: 25710580
[TBL] [Abstract][Full Text] [Related]
17. High serum microRNA-335 level predicts aggressive tumor progression and unfavorable prognosis in pediatric acute myeloid leukemia.
Lin X; Wang Z; Zhang R; Feng W
Clin Transl Oncol; 2015 May; 17(5):358-64. PubMed ID: 25301405
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia.
Zhang TJ; Wu DH; Zhou JD; Li XX; Zhang W; Guo H; Ma JC; Deng ZQ; Lin J; Qian J
J Cell Physiol; 2018 Apr; 233(4):3274-3281. PubMed ID: 28884855
[TBL] [Abstract][Full Text] [Related]
19. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
20. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Schnittger S; Schoch C; Dugas M; Kern W; Staib P; Wuchter C; Löffler H; Sauerland CM; Serve H; Büchner T; Haferlach T; Hiddemann W
Blood; 2002 Jul; 100(1):59-66. PubMed ID: 12070009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]